Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent consensus recommendations suggest starting hypoglycemia treatment with 5 to 10 g of simple carbohydrates for automated insulin delivery systems where insulin pump algorithms integrate real-time data from continuous glucose monitors [28].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are separate consensus recommendations for people using automated insulin delivery who experience a hypoglycemia caused by exercise or excessive bolus of rapid-acting insulin [28].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“By 2023, six out of these proposed algorithms advanced to systems accepted in the clinical practice: Medtronic 670G/770G, Medtronic 780G, CamAPS FX developed in Cambridge, UK, the French system Diabeloop, Tandem's Control-IQ, and Insulet's Omnipod 5. 112”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationUpdated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals
Flanagin, A., Frey, T., Christiansen, S. L., & AMA Manual of Style Committee (2021) · JAMA · doi:10.1001/jama.2021.13304 · Cited by 1,615
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationHolt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citation
Research works printed but not linked: 1
- 28. Ware J, Allen JM, Boughton CK, et al. Randomized trial of closedloop control in very young children with type 1 diabetes. N Engl J Med. 2022; 386 (3):209-219.
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Self-citation6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Self-citation7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Beverly, E. A., Bruemmer, D., Collins, B. S., Darville, A., Ekhlaspour, L., Hassanein, M., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s005 · Cited by 285
Self-citation7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Self-citationAutomated insulin delivery in women with pregnancy complicated by type 1 diabetes
Lee, T. T. M., Collett, C., Bergford, S., Hartnell, S., Scott, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Barnard-Kelly, K., Rankin, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303911 · Cited by 241
Self-citation9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Self-citation6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Self-citation7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 288
Self-citationBenhalima, K., Beunen, K., Van Wilder, N., Ballaux, D., Vanhaverbeke, G., Taes, Y., Aers, X.-P., Nobels, F., Marlier, J., Lee, D., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00089-5 · Cited by 131
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s005 · Cited by 265
Self-citationJacobs, P. G., Herrero, P., Facchinetti, A., Vehi, J., Kovatchev, B., Breton, M. D., Cinar, A., Nikita, K. S., Doyle, F. J., Bondia, J., et al. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2023.3331297 · Cited by 113
“Best practice 32: When designing ML algorithms used within a closed-loop system, the outcome metrics [172] should be considered to minimize risk to the user.”
MethodSelf-citationArtificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Zeng, B., Gao, L., Yang, Q., Jia, H., & Sun, F. (2023) · Diabetes Care · doi:10.2337/dc23-0504 · Cited by 100
New advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
Self-citationMcVean, J., Forlenza, G. P., Beck, R. W., Bauza, C., Bailey, R., Buckingham, B., DiMeglio, L. A., Sherr, J. L., Clements, M., Neyman, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.2063 · Cited by 85
Self-citationThe Artificial Pancreas and Type 1 Diabetes
Nwokolo, M., & Hovorka, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad068 · Cited by 119
“Optimal care for those using advanced technologies also comprises standard diabetes care processes, including blood pressure, renal, and retinopathy screening and foot risk stratification alongside well-being and technical support (17, 48, 64).”
BackgroundInfluentialSelf-citationDi Molfetta, S., Di Gioia, L., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., Strippoli, G. F. M., Sorice, G. P., Perrini, S., Natalicchio, A., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3842 · Cited by 76
“Given the pre-liminary indications of efficacy and safety in this population, a consensus of experts recommends considering the initiation of appropriate HCL systems in patients with type 2 diabetes [23].”
Moser, O., Zaharieva, D. P., Adolfsson, P., Battelino, T., Bracken, R. M., Buckingham, B. A., Danne, T., Davis, E. A., Dovč, K., Forlenza, G. P., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06308-z · Cited by 111
“1 [1–4]), recommendations on using current commercially available automated insulin delivery (AID) systems for PA are limited [5–8].”
Self-citationPasqua, M.-R., Tsoukas, M. A., Kobayati, A., Aboznadah, W., Jafar, A., & Haidar, A. (2025) · Nature Medicine · doi:10.1038/s41591-024-03463-z · Cited by 68
Self-citationBenhalima, K., Beunen, K., Siegelaar, S. E., Painter, R., Murphy, H. R., Feig, D. S., Donovan, L. E., Polsky, S., Buschur, E., Levy, C. J., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00116-x · Cited by 61
Self-citationSemaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Self-citationReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
Self-citationDigital Technology for Diabetes
Hughes, M. S., Addala, A., & Buckingham, B. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2215899 · Cited by 59
Self-citationThe role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
Self-citationGrassi, B., Gómez, A. M., Calliari, L. E., Franco, D., Raggio, M., Riera, F., Castro, M., McVean, J., van den Heuvel, T., Arrieta, A., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15023 · Cited by 55
“The MiniMed 780G system has been shown to achieve safely the internationally recommended glycaemic targets, both in clinical trials as in real-world analyses.4-7 Currently, there are large disparities in racial, ethnic and regional representation in clinical studies as well as in real-world studies on the use and outc…”
BackgroundBeato-Víbora, P. I., Chico, A. I., Moreno-Fernández, J., Bellido, V., Nattero‐Chávez, L., César, M. J. P., Martínez‐Brocca, M. A., Giménez, M., Aguilera, E., Climent, E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1355 · Cited by 62
Karakus, K. E., Akturk, H. K., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N. (2023) · Diabetes Care · doi:10.2337/dc23-0495 · Cited by 52
Self-citationContinuous ketone monitoring: Exciting implications for clinical practice
Kong, Y. W., Morrison, D., Lu, J., Lee, M. H., Jenkins, A. J., & O'Neal, D. N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15921 · Cited by 61
Self-citationRenard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., Kovatchev, B. P., & iDCL Trial Research Group (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 51
“All hyperglycemic events, with or without ketosis or keto-acidosis, were related to insulin-infusion-set failures and should be preventable by reinforcement education (36).”
BackgroundSelf-citationKarges, B., Rosenbauer, J., Stahl‐Pehe, A., Flury, M., Biester, T., Tauschmann, M., Lilienthal, E., Hamann, J., Galler, A., & Holl, R. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00284-5 · Cited by 63
Self-citationDeveloping the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationPemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
“However, the Medtrum TouchCare Nano System has CE marking from Notified Body 0197, TÜV Rheinland LGA Products,(43) for AID use in adults and paediatrics with type 1 diabetes and was not mentioned in the international consensus statement.(63) It has been used in clinical care in some centres in the UK without published…”
MethodSelf-citationTrends and Disparities in Technology Use and Glycemic Control in Type 1 Diabetes
Fang, M., Xu, Y., Ballew, S. H., Coresh, J., Echouffo-Tcheugui, J. B., Selvin, E., & Shin, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26353 · Cited by 47
Griffin, T. P., Gallen, G., Hartnell, S., Crabtree, T. S. J., Holloway, M., Gibb, F. W., Lumb, A. N., Wilmot, E. G., Choudhary, P., & Hussain, S. (2023) · Diabetic Medicine · doi:10.1111/dme.15078 · Cited by 54
Self-citationZaharieva, D. P., Morrison, D., Paldus, B., Lal, R., Buckingham, B. A., & O'Neal, D. N. (2023) · Diabetes Spectrum · doi:10.2337/dsi22-0018 · Cited by 48
“Open-source AID systems allow initiation of temporary profiles and override presets that can temporarily reduce the aggressiveness of the carbohydrate-to-insulin ratio, which allows for accurate recording of carbohydrates (11).”
BackgroundSelf-citationCriego, A. B., Carlson, A. L., Brown, S. A., Forlenza, G. P., Bode, B. W., Levy, C. J., Hansen, D. W., Hirsch, I. B., Bergenstal, R. M., Sherr, J. L., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0364 · Cited by 49
Self-citationThe double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
“Improvements in technological devices for diabetes management, such as continuous and intermittent glucose monitoring and hybrid closed-loop systems have improved glycemic control and resulted in overall decreases in the rates of hypoglycemia and as well as improved GV [116, 174].”
BackgroundReal-World Evidence Analysis of a Hybrid Closed-Loop System
Alwan, H., Wilinska, M. E., Ruan, Y., Silva, J. D., & Hovorka, R. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231185348 · Cited by 43
Self-citationLombardo, F., Passanisi, S., Alibrandi, A., Bombaci, B., Bonfanti, R., Delvecchio, M., Candia, F. D., Mozzillo, E., Piccinno, E., Piona, C. A., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0491 · Cited by 43
“35 Although studies evaluating the safety and efficacy of early AHCL use in adults and children at the onset of diabetes are still ongoing, it is proposed that early initiation could be related to good long-term glucose control, long-term device acceptance, and durable use.”
Renard, É., Weinstock, R. S., Aleppo, G., Bode, B. W., Brown, S. A., CASTORINO, K. N., Hirsch, I. B., Kipnes, M. S., Laffel, L. M., Lal, R., et al. (2024) · Diabetes Care · doi:10.2337/dc24-1550 · Cited by 46
Self-citationPolsky, S., Buschur, E., Dungan, K., Garcetti, R., Nease, E., Malecha, E., Bartholomew, A., Johnson, C., Pyle, L., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0012 · Cited by 39
“WhileHCLwear has been studied extensively in numerous nonpregnant populations (e.g., different age groups, different types of diabetes) and situations (e.g., exercise conditions, diabetes comorbidities), 32 it is still relatively understudied in pregnancy.”
Dovč, K., Bergford, S., Fröhlich-Reiterer, E. E., Zaharieva, D. P., Potočnik, N., Müller, A., Lenarčič, Ž., Calhoun, P. M., Fritsch, M., Sourij, H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0178 · Cited by 44
“11 To further improve postprandial glycemic outcomes, significantly faster insulin analogues 33 or adjunctive therapies are likely needed.”
Self-citationReal‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis
Yang, Q., Zeng, B., Hao, J., Yang, Q., & Sun, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15718 · Cited by 46
Kovatchev, B. P., Castillo, A., Pryor, E. C., Kollar, L. L., Barnett, C. L., DeBoer, M. D., Brown, S. A., & for the NAP Study Team (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0469 · Cited by 46
“13 Consensus recommendations for the use of AID technologies in clinical practice were published by Endocrine Reviews, 14 to serve as a comprehensive guide for clinicians interested in utilizing the advantages of AID therapy.”
Self-citationShah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“102 With overwhelming evidence to support these technologies, the American Diabetes Association Standards of Care 2024 recommends the use of AID systems for the management of T1D.”
Self-citationThe changing landscape of automated insulin delivery in the management of type 1 diabetes
Lakshman, R., Boughton, C. K., & Hovorka, R. (2023) · Endocrine Connections · doi:10.1530/ec-23-0132 · Cited by 49
Self-citationMesser, L. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0308 · Cited by 37
“17 It is therefore not surprising that 54% had C:I ratios that were more aggressive than the AACE guidelines (450/TDI).”
BackgroundSelf-citationVisser, H. S. D., Waraich, S., Chhabra, M., Yamamoto, J. M., Zenlea, I. S., Askin, N., Rabbani, R., McGavock, J., TEAM Trial Patient Coresearchers, Greenberg, D. T., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2740 · Cited by 43
Reznik, Y., Carvalho, M., Fendri, S., Prevost, G., Chaillous, L., Riveline, J. P., Hanaire, H., Dubois, S., Houéto, P., Pasche, H., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15351 · Cited by 34
Key indices of glycaemic variability for application in diabetes clinical practice
Monnier, L., Bonnet, F., Colette, C., Renard, É., & Owens, D. R. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101488 · Cited by 36
Nwokolo, M., Lakshman, R., Hartnell, S., Alwan, H., Ware, J., Allen, J. M., Wilinska, M. E., Evans, M. L., Hovorka, R., & Boughton, C. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0262 · Cited by 34
Self-citationLee, M. Y., Seav, S. M., Ongwela, L., Lee, J. J., Aubyrn, R., Cao, F. Y., Kalinsky, A., Aparicio Ramos, O., Gu, Y., Kingston, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0626 · Cited by 32
Self-citationStahl‐Pehe, A., Mashhadi, N. S., Wirth, M., Schlesinger, S., Kuß, O., Holl, R. W., Bächle, C., Warz, K.-D., Bürger-Büsing, J., Spörkel, O., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103190 · Cited by 42
Cordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., McVean, J., Lee, S. W., Slover, R. H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0123 · Cited by 30
Self-citationWang, X., Si, J., Li, Y., Tse, P., Zhang, G., Wang, X., Ren, J., Xu, J., Sun, J., & Yao, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01819-0 · Cited by 33
“The application of AI algorithms in automated insulin delivery (AID) and CGM systems [29–31] has created closed-loop systems resembling an artificial pancreas [32, 33].”
Wang, Y., Lu, J., Yu, J., Ni, J., Wang, M., Lu, W., Zhu, W. M., Guo, J., Bao, Y., & Zhou, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16143 · Cited by 32
Benhalima, K., Durnwald, C. P., Sweeting, A., Adams, D., Addala, A., Battelino, T., Bergenstal, R. M., Carlson, A. L., Donovan, L., Franco, D. R., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00335-3 · Cited by 37
Self-citationThrasher, J. R., Arrieta, A., Niu, F., Cameron, K. R., Cordero, T. L., Shin, J., Rhinehart, A. S., & Vigersky, R. A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0453 · Cited by 33
Type 1 diabetes-related distress: Current implications in care
Rodríguez-Muñoz, A., César, M. J. P., Tinahones, F. J., & Martínez‐Montoro, J. I. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.03.030 · Cited by 35
Ware, J., Allen, J. M., Boughton, C. K., Cezar, A., Hartnell, S., Wilinska, M. E., Thankamony, A., Deakin, M., Leyland, H., Phelan, K., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0042 · Cited by 28
Self-citationMichaels, V. R., Boucsein, A., Watson, A. S., Frewen, C. M., Sanders, O. J., Haszard, J. J., Jones, S., Milford-Hughes, P. J., de Bock, M. I., & Wheeler, B. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0334 · Cited by 28
“15,16 We have previously published positive 3-month data on transitioning youth with suboptimal glycemia from MDI to advanced hybrid closed loop (AHCL) therapy.”
Hirsch, I. B., Beck, R. W., Marak, M. C., Kudva, Y. C., Aktürk, H. K., Bhargava, A., Codorniz, K., Diner, J., Aleppo, G., Blevins, T., et al. (2024) · Diabetes Care · doi:10.2337/dc24-1832 · Cited by 30
Self-citationAutomated Insulin Delivery for Pregnant Women With Type 1 Diabetes: Where Do We Stand?
Benhalima, K., JENDLE, J. H., Beunen, K., & Ringholm, L. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223934 · Cited by 28
“19,20 Outside of pregnancy, the use of AID has led to a paradigm shift in the management of T1D, with a 10% higher time in range (TIR; 3.9-10.0 mmol/L or 70-180 mg/dL), with low hypoglycemia risk and improved quality of life compared with stand-alone insulin pumps.”
InfluentialPiona, C. A., Passanisi, S., Bombaci, B., Marigliano, M., Lombardo, F., Mancioppi, V., Morandi, A., Maffeis, C., Salzano, G., & ISPED Diabetes Study Group (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15791 · Cited by 30
Closed-loop systems: recent advancements and lived experiences
Kadiyala, N., Hovorka, R., & Boughton, C. K. (2024) · Expert Review of Medical Devices · doi:10.1080/17434440.2024.2406901 · Cited by 33
Self-citationAktürk, H. K., Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T. R. A., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0432 · Cited by 27
Self-citationLee, T., Collett, C., Bergford, S., Hartnell, S., SCOTT, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Reynolds, R. M., Wilinska, M. E., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00340-1 · Cited by 27
Self-citationMcCarthy, O. M., Christensen, M. B., Kristensen, K. B., Schmidt, S., Ranjan, A. G., Bain, S. C., Bracken, R. M., & Nørgaard, K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0009 · Cited by 26
“7 The heightened bioenergetic demands of exercise induce large increases in intramuscular glucose disposal.”
Self-citationAskari, M. R., Ahmadasas, M., Shahidehpour, A., Rashid, M. M., Quinn, L., Park, M., & Çınar, A. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204884 · Cited by 27
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Lindkvist, E. B., Laugesen, C., Reenberg, A. T., Ritschel, T. K. S., Svensson, J., Jørgensen, J. B., Nørgaard, K., & Ranjan, A. G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1073388 · Cited by 22
Self-citationAl‐Sofiani, M. E., Alharthi, S. K., Albunyan, S., Alzaman, N. S., Klonoff, D. C., & Alguwaihes, A. M. (2024) · Diabetes Care · doi:10.2337/dc23-1968 · Cited by 24
Self-citationOprea, A. D., Kalra, S. K., Duggan, E. W., Russell, L., Urman, R. D., Abdelmalak, B., Patel, P., Pfeifer, K. J., Grant, P., Charitou, M. M., et al. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111627 · Cited by 22
Self-citationYu, X., Yang, Z., Sun, X., Liu, H., Li, H., Lu, J., Zhou, J. H., & Çınar, A. (2025) · AI · doi:10.3390/ai6050087 · Cited by 31
Elbarbary, N. S., & Ismail, E. A. R. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01184-w · Cited by 20
“These advanced hybrid closed loop (AHCL) systems utilize an algorithm that automatically adjusts insulin delivery via an insulin pump based on real-time sensor glucose levels [2].”
MethodJacobs, P. G., Marak, M. C., Calhoun, P. M., Gal, R. L., Castle, J. R., & Riddell, M. C. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111874 · Cited by 21
Self-citationClosed-Loop Control, Artificial Intelligence–Based Decision-Support Systems, and Data Science
Nimri, R., Phillip, M., Clements, M. A., & Kovatchev, B. P. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2505 · Cited by 26
“International consortiums published clinical guidelines for the use of AID in the clinical practice (1,25– 27).”
Self-citationLaugesen, C., Ritschel, T., Ranjan, A. G., Hsu, L. J., Jørgensen, J. B., Svensson, J., Ekhlaspour, L., Buckingham, B. A., & Nørgaard, K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0022 · Cited by 25
Self-citationGlycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure
Klein, K. R., Lingvay, I., Tuttle, K. R., & Flythe, J. E. (2024) · Diabetes Care · doi:10.2337/dci24-0081 · Cited by 27
Closed-Loop and Artificial Intelligence–Based Decision Support Systems
Nimri, R., Phillip, M., & Kovatchev, B. P. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2505 · Cited by 22
Self-citationCambuli, V. M., & Baroni, M. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713139 · Cited by 20
“In preschool children [75], adults aged 65 and older, and women with type 1 diabetes pre-existing to pregnancy, numerous studies do not yet allow a recommendation level A [74].”
BackgroundResultReducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
Forlenza, G. P., Dai, Z., Niu, F., & Shin, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0459 · Cited by 25
Self-citationThe Future of Automated Insulin Delivery Systems
Hughes, M. S., & Levy, C. J. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.05.752 · Cited by 20
Chico, A. I., Moreno-Fernández, J., Fernández‐García, D., & Solá, E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01486-2 · Cited by 23
Bergenstal, R. M. (2023) · Diabetes Spectrum · doi:10.2337/dsi23-0005 · Cited by 20
Self-citationBismuth, É., Tubiana‐Rufi, N., Rynders, C. A., Dalla‐Vale, F., Bonnemaison, É., Coutant, R., Farret, A., Poidvin, A., Bouhours‐Nouet, N., Storey, C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0916 · Cited by 19
Self-citationAkturk, H. K., American Diabetes Association Diabetes Technology Interest Group, Aloi, J., Shah, V. N., Akturk, H. K., McKee, A. M., Ekhlaspour, L., Kim, S., & Everett, E. (2024) · Clinical Diabetes · doi:10.2337/cd23-0080 · Cited by 16
Self-citationDovč, K., Neuman, V., Gemulla, G., Cherubini, V., Alonso, G. T., Fritsch, M., Boettcher, C., de Beaufort, C. E., Holl, R. W., & de Bock, M. I. (2025) · Diabetes Care · doi:10.2337/dc24-2483 · Cited by 22
Off-label use of an automated insulin delivery system in pregnant women with type 1 diabetes
Albert, L., Romero, A., Capel, I., Cano, A., Subías, D., Casamitjana, L., Mazarico, I., & Rigla, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110800 · Cited by 16
Rizzi, A., Tartaglione, L., Paoli, L. L., Leo, M. L., Popolla, V., Viti, L., Barberio, A., Leo, M. A. S. D., Pontecorvi, A., & Pitocco, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15766 · Cited by 16
“…these systems showed better glucose outcomes (e.g. increased TIR, improved HbA1c, reduced hypoglycaemic events) when compared with baseline or other insulin therapies (multiple daily injections [MDI], continuous subcutaneous insulin infusion [CSII] and sensor-augmented pump [SAP] 17,23,24 ).”
Glycemia Risk Index Assessment in a Pediatric and Adult Patient Cohort With Type 1 Diabetes Mellitus
Díaz-Soto, G., Pérez-López, P., Fernández-Velasco, P., de la Marca, M. D. L. O. N., Delgado, E., Simón, S. D. A., de Luis, D. A., & Bahillo-Curieses, P. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231154561 · Cited by 17
Abegaz, T. M., Ahmed, M. B., Sherbeny, F., Diaby, V., Chi, H., & Ali, A. A. (2023) · Healthcare · doi:10.3390/healthcare11081138 · Cited by 22
Advances in diabetes technology within the digital diabetes ecosystem
Aktürk, H. K., & Bindal, A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.10-b.s7 · Cited by 22
Medina, A. M. G., Henao, D. C., Yepes, C. A., Silva, J., González, J. A. G., Cortés, D., Robledo, S., Mejía, G., & Rondón, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110897 · Cited by 14
Haliloğlu, B., Boughton, C. K., Lakshman, R., Ware, J., Nwokolo, M., Thabit, H., Mader, J. K., Bally, L., Leelarathna, L., Wilinska, M. E., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0509 · Cited by 16
“3 However, these systems face limitations, due to the relatively slow absorption rate of subcutaneously administered rapid-acting insulin analogs.”
Self-citationTechnology advances in diabetes pregnancy: right technology, right person, right time
McLean, A., Maple-Brown, L. J., & Murphy, H. R. (2024) · Diabetologia · doi:10.1007/s00125-024-06216-2 · Cited by 22
“Outside of pregnancy, hybrid closed-loop (HCL) systems are increasingly used in type 1 diabetes management [24, 25].”
BackgroundSelf-citationResmini, E., Zarra, E., Dotti, S., Rotondi, G., Cornaghi, A. V., Madaschi, S., Cimino, E., Massari, G., Pezzaioli, L. C., Buoso, C., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01946-w · Cited by 14
“The increase in TIR and reduction in TAR represent expected results and are in line with those produced by experimental single-brand and observational clinical studies [24–26].”
Result
Metadata
- Authors
- Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., Amiel, S. A., Bally, L., Beck, R. W., Biester, S., Biester, T., Blanchette, J. E., Bosi, E., Boughton, C. K., Breton, M. D., Brown, S. A., Buckingham, B. A., Cai, A., Carlson, A. L., Castle, J. R., Choudhary, P., Close, K. L., Cobelli, C., Criego, A. B., Davis, E., de Beaufort, C., de Bock, M. I., DeSalvo, D. J., DeVries, J. H., Dovc, K., Doyle, F. J., Ekhlaspour, L., Shvalb, N. F., Forlenza, G. P., Gallen, G., Garg, S. K., Gershenoff, D. C., Gonder-Frederick, L. A., Haidar, A., Hartnell, S., Heinemann, L., Heller, S., Hirsch, I. B., Hood, K. K., Isaacs, D., Klonoff, D. C., Kordonouri, O., Kowalski, A., Laffel, L., Lawton, J., Lal, R. A., Leelarathna, L., Maahs, D. M., Murphy, H. R., Nørgaard, K., O’Neal, D., Oser, S., Oser, T., Renard, E., Riddell, M. C., Rodbard, D., Russell, S. J., Schatz, D. A., Shah, V. N., Sherr, J. L., Simonson, G. D., Wadwa, R. P., Ward, C., Weinzimer, S. A., Wilmot, E. G., & Battelino, T.
- Affiliations
- Tel Aviv University (IL)
- HealthPartners (US)
- Southern Health NHS Foundation Trust (GB)
- Kinderkrankenhaus auf der Bult (DE)
- University of Cambridge (GB)
- University of Virginia (US)
- University of Colorado Anschutz (US)
- CGParkin Communications, Inc. , Henderson, NV , USA
- Joslin Diabetes Center (US)
- King's College London (GB)
- University of Bern (CH)
- Jaeb Center for Health Research (US)
- University of Utah (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- Close Concerns (United States) (US)
- Oregon Health & Science University (US)
- University of Leicester (GB)
- University of Padua (IT)
- The Kids Research Institute Australia (AU)
- Diabetes & Endocrine Care Clinique Pédiatrique DECCP/Centre Hospitalier Luxembourg, and Faculty of Sciences, Technology and Medicine, University of Luxembourg, Esch sur Alzette, GD Luxembourg/Department of Paediatrics, UZ-VUB , Brussels , Belgium
- Department of Paediatrics, University of Otago , Christchurch , New Zealand
- Baylor College of Medicine (US)
- Amsterdam University Medical Centers (NL)
- Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, UMC - University Children’s Hospital, Ljubljana, Slovenia, and Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia
- Harvard University (US)
- Lucile Packard Children's Hospital (US)
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel , 49202 Petah Tikva , Israel
- McGill University (CA)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Science Consulting in Diabetes GmbH , Kaarst , Germany
- University of Sheffield (GB)
- University of Washington (US)
- Cleveland Clinic (US)
- Diabetes Research Institute, Mills-Peninsula Medical Center , San Mateo, CA 94010 , USA
- Breakthrough T1D (US)
- University of Edinburgh (GB)
- University of Manchester (GB)
- University of East Anglia (GB)
- University of Copenhagen (DK)
- Department of Medicine and Department of Endocrinology, St Vincent’s Hospital Melbourne, University of Melbourne , Melbourne , Australia
- Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM , Montpellier , France
- York University (CA)
- Biomedical Informatics Consultants LLC , Potomac, MD , USA
- University of Florida (US)
- Yale University (US)
- University of Nottingham (GB)
- University of Ljubljana (SI)
- Corresponding author
- Phillip, Moshe
- Nimri, Revital
- ORCID
- Phillip, Moshe
- Nimri, Revital
- Bergenstal, Richard M
- Barnard-Kelly, Katharine
- Danne, Thomas
- Hovorka, Roman
- Kovatchev, Boris P
- Messer, Laurel H
- Parkin, Christopher G
- Amiel, Stephanie A
- Bally, Lia
- Beck, Roy W
- Biester, Torben
- Blanchette, Julia E
- Bosi, Emanuele
- Boughton, Charlotte K
- Breton, Marc D
- Brown, Sue A
- Buckingham, Bruce A
- Carlson, Anders L
- Castle, Jessica R
- Choudhary, Pratik
- Close, Kelly L
- Cobelli, Claudio
- Criego, Amy B
- Davis, Elizabeth
- de Beaufort, Carine
- de Bock, Martin I
- DeSalvo, Daniel J
- DeVries, J Hans
- Dovc, Klemen
- Doyle, Francis J
- Ekhlaspour, Laya
- Shvalb, Naama Fisch
- Forlenza, Gregory P
- Gallen, Geraldine
- Garg, Satish K
- Gonder-Frederick, Linda A
- Haidar, Ahmad
- Hartnell, Sara
- Heinemann, Lutz
- Heller, Simon
- Hirsch, Irl B
- Hood, Korey K
- Isaacs, Diana
- Klonoff, David C
- Kordonouri, Olga
- Kowalski, Aaron
- Laffel, Lori
- Lawton, Julia
- Lal, Rayhan A
- Leelarathna, Lalantha
- Maahs, David M
- Murphy, Helen R
- Nørgaard, Kirsten
- Oser, Sean
- Oser, Tamara
- Renard, Eric
- Riddell, Michael C
- Rodbard, David
- Russell, Steven J
- Schatz, Desmond A
- Shah, Viral N
- Sherr, Jennifer L
- Simonson, Gregg D
- Wadwa, R Paul
- Weinzimer, Stuart A
- Wilmot, Emma G
- Battelino, Tadej
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2022-09-06
- Volume
- 44
- Issue
- 2
- Pages
- 254-280
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC9985411
- OpenAlex
- W4294783598
- Semantic Scholar
- 28646f57b5b3cbcfac8f10ea51308aadbf9e4f00
- Cited by
- 443
- References
- 144
- Citations by year
- 2026: 102 · 2025: 121 · 2024: 141 · 2023: 76 · 2022: 3
- FWCI
- 63.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by-nc-nd)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- HAL (submittedVersion, cc-by-nc-nd)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by-nc-nd)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Open Access CRIS of the University of Bern
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Bigfoot Biomedical
- Insulet Corporation
- MannKind Corporation
- Dexcom
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- Cardinal Health
- Tandem Diabetes Care
- National Institute for Health and Care Research (16/35/01, CL-2020-14-801)
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- University of Colorado Denver
- Abbott Diabetes Care
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942, K23DK122017, R01DK129553, P30DK045735)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- artificial pancreas, diabetes management, glycemic control, hypoglycemia risk, insulin pump therapy, continuous glucose monitoring, eligibility criteria, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.